Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1c by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
|Videos|December 11, 2021
How Microbiome-based Therapeutics May Impact Treatment Landscape for C. Diff Infection, Recurrent C. Diff Infection
Teena Chopra, MD, MPH, professor of infectious diseases at Wayne State University, discussed how microbiome-based therapeutics may impact the current treatment landscape for C. diff infection and recurrent C. diff infection.
Advertisement
Pharmacy Times interviewed Teena Chopra, MD, MPH, professor of infectious diseases at Wayne State University, on her presentation at the American Society of Health-System Pharmacists 2021 Midyear Clinical Meeting on whether the power of the microbiome can be unlocked to break the cycle of recurrent Clostridioides difficile (C. diff) infection.
During the interview, Chopra discussed how microbiome-based therapeutics may impact the current treatment landscape for C. diff infection and recurrent C. diff infection.
Advertisement
Related to this article
fMRI data show cagrilintide-semaglutide altered brain responses to high-calorie food cues; REIMAGINE analyses point to ectopic fat and bone effects.
A Novo Nordisk–funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, although the findings cannot show causation.
A new analysis finds a significant weight loss edge for tirzepatide under one estimand but not another; no head-to-head trial exists at these doses.
Indirect comparison links orforglipron 17.2 mg to 1.5% more weight loss and 0.3% more A1C lowering than oral semaglutide 25 mg in adults with type 2 diabetes.
Phase 3 TRIUMPH-2 data presented at EASD show HbA1C reductions up to 1.6%, with GI effects, hypotension, and dysesthesia as key counseling points.
Approval spans early and levodopa-treated disease; a 6-week titration and CYP3A interactions put pharmacists at the center of starting therapy.
Phase 2 MILESTONE results suggest that postinduction minimal residual disease (MRD) negativity can identify a small subset of transplant-eligible patients with newly diagnosed multiple myeloma who may defer autologous stem cell transplantation.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Why Lp(a) Testing Lagged Behind LDL Cholesterol Screening
2
Statin Myths: Why Patients Avoid Cholesterol-Lowering Therapy
3
Pharmacist, Advocate, Ally: Delivering Comprehensive Gender-Affirming Care
4
Semaglutide 2 mg Tied to Lower MACE Risk Than Tirzepatide Switch
5